Federal Circuit Affirms Presumption of Separateness in Regeneron Pharmaceuticals, Inc. v. Mylan Pharmaceuticals Inc. et al., C.A. No. 24-2351 (Fed. Cir. Mar. 14, 2025)

In a formulation claim, if elements are listed separately, does this necessarily entail that those elements are “separate and distinct components”?  This was the question before the district court in Regeneron Pharmaceuticals, Inc. v. Mylan Pharmaceuticals Inc. et al. and up for appeal at the Federal Circuit....
By: Haug Partners LLP

Array